Company profile
THC Biomed Intl Ltd.
OTC: THCBF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Kelowna, BCReports USD
#801 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 38
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, return on assets · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$2.2M
Rev growth YoY (TTM)
-22.0%
Net income (FY)
-$2.4M
Employees
35
as of 2026-08-27
Market cap
$205.0k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M2.4M CAD2022
Net income-$2.4M-3.1M CAD2022
Operating income-$2.1M-2.7M CAD2022
Total assets$11.5M14.7M CAD2022
Liabilities$6.1M7.8M CAD2022
Equity$5.4M6.9M CAD2022
Revenue trend
FY2017 – FY2022 · USD
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is THC Biomed Intl Ltd.’s revenue?
THC Biomed Intl Ltd. booked $1.9M in FY2022 revenue, contracting 35% year over year — slower than 77% of Healthcare companies we track, at a -125.2% net margin.
Peers · Healthcare
Rapid Dose Therapeutics Corp.38DPressure BioSciences, Inc.——Lipocine Inc.48DiSpecimen Inc.29DAnteris Technologies Global Corp.32DLongevity Health Holdings Inc.22DKey facts
CEOJohn Miller
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersKelowna, BC
ExchangeOTC: THCBF
Employees35
IPO date2018-03-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.